KALV
KalVista Pharmaceuticals, Inc. · Healthcare
Chief Development Officer Christopher Yea sold $58K of KalVista Pharmaceuticals, Inc.
Sold$58,256
$13.45Price
4,331Shares
−2%Stake
What KALV did after the filing
- The stock from Wed, Nov 26 close, $14.10
- +16.2%
- S&P 500, same days
- +3.1%
Measured over 30 trading days, to the Jan 12 close.
Traded Mon, Nov 24. Filed Wed, Nov 26, 1:49 PM ET, during the session. Returns use the Nov 26 close and the Jan 12 close. Not investment advice.